Broadcast Date: 
  • Time: 

Among many exciting precision medicine strategies, RNA-based therapeutics are  rapidly growing in popularity and effectiveness. Although progress has been achieved  in developing RNA-targeted delivery carriers (mainly by using monoclonal antibodies for targeting), their clinical translation has yet to be fully recognized. This is due, in no small part, to massive development and production requirements and high batch-to-batch variability of current technologies, which currently rely on chemical conjugation. Novel synthesis methodologies could help vault these therapeutic strategies into the market and patients much more quickly.

In this webinar from GEN and The CRISPR Journal, Professor Dan Peer will discuss the state of RNA-based therapeutics, particularly developing a self-assembled modular  platform that enables the construction of a theoretically unlimited repertoire of RNA-targeted carriers. He will present a novel approach for delivering modified mRNA to specific cell types in vivo utilizing this platform. Dr. Peer will also share recent data on mRNA vaccines for COVID-19 and very high-efficiency genome editing in glioma and metastatic ovarian cancer—developed using this methodology.

A live Q&A session followed the presentation, offering you a chance to pose questions to our expert panelist.


Webinar produced with support from:

Dan Peer, PhD
Dan Peer, PhD

Professor, Director of the Laboratory of Precision NanoMedicine

Vice President for Research and Development Tel Aviv University